Patient characteristics and CMV disease/infection after allogeneic SCT
| Patient no. . | Age, y* . | Diagnosis . | Graft . | CMV IgG donor/recipient . | Body weight, kg . | Conditioning regimen . | GVHD prophylaxis . | GVHD status before T-cell transfer . | GVHD prophylaxis at T-cell transfer . | GVHD status at T-cell transfer . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 16 | AML | Haplo | +/+ | 45 | Flu, TT, Mel, OKT3 | CSA. MMF | Skin III, gut I° | CSA. MMF | Skin I |
| 2 | 5 | AML | MUD | +/+ | 15 | Flu, TT, Treo, ATG | CSA, MMF | Skin II° | — | — |
| 3 | 9 | ALL | Haplo | +/+ | 19 | Flu, TT, Mel, OKT3 | MMF | — | — | — |
| 4 | 36 | NHL | MUD | +/− | 60 | Flu, Mel, Alemtuzumab | CSA | Skin I | CSA | — |
| 5 | 17 | ALL | Haplo | +/+ | 34 | Clo, TT, Mel, OKT3 | MMF | — | MMF | — |
| 6 | 0.4 | Tay-Sachs | Haplo | +/+ | 5 | Bu, Cy, TT, OKT3 | MMF | — | — | — |
| 7 | 59 | AML | Haplo | +/+ | 80 | Flu, Mel, TT, OKT3 | MMF | Gut III | MMF | — |
| 8 | 13 | RMS | Haplo | +/+ | 60 | Flu, Cy Treo | CSA, MTX | — | CSA | — |
| 9 | 6 | ALL | Haplo | +/+ | 18 | Clo, TT, Mel, OKT3 | MMF | Skin I, gut II, BOOP | MMF, Etanercept | Gut I |
| 10 | 52 | AML | Haplo | +/+ | 65 | Flu, TT, TLI, OKT3 | — | — | — | — |
| 11 | 20 | ALL | Third-party MMUD after cord blood SCT | −/+ | 52 | Flu, Cy, OKT3 | CSA, MMF | Skin II | — | — |
| 12 | 37 | MDS | MUD | +/+ | 63 | Bu, Cy, Alemtuzumab | CSA, MMF | Skin I-II (suspected) | CSA | — |
| 13 | 48 | ALL | MMUD | +/+ | 62 | TBI, Cy, ATG | CSA, MTX | — | CSA, Prednisolone | — |
| 14 | 7 | JMML | Haplo | +/+ | 17 | Bu, Cy, Mel, OKT3 | MMF | — | — | — |
| 15 | 42 | AML | MRD | +/+ | 55 | Flu, Bu, ATG | CSA | Skin II | — | — |
| 16 | 7 | ALL | Haplo | +/+ | 18 | Flu, TT, Mel, OKT3 | CSA, MMF | Skin II and gut III | Tacrolimus, MMF | Skin I |
| 17 | 46 | AML | Third-party MMUD after cord blood SCT | −/+ | 84 | Flu, Cy | CSA; MMF | Gut I-II | MMF | Gut I |
| 18 | 26 | AML | Haplo | +/+ | Flu, TT, Mel, OKT3 | — | — | — | — |
| Patient no. . | Age, y* . | Diagnosis . | Graft . | CMV IgG donor/recipient . | Body weight, kg . | Conditioning regimen . | GVHD prophylaxis . | GVHD status before T-cell transfer . | GVHD prophylaxis at T-cell transfer . | GVHD status at T-cell transfer . |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 16 | AML | Haplo | +/+ | 45 | Flu, TT, Mel, OKT3 | CSA. MMF | Skin III, gut I° | CSA. MMF | Skin I |
| 2 | 5 | AML | MUD | +/+ | 15 | Flu, TT, Treo, ATG | CSA, MMF | Skin II° | — | — |
| 3 | 9 | ALL | Haplo | +/+ | 19 | Flu, TT, Mel, OKT3 | MMF | — | — | — |
| 4 | 36 | NHL | MUD | +/− | 60 | Flu, Mel, Alemtuzumab | CSA | Skin I | CSA | — |
| 5 | 17 | ALL | Haplo | +/+ | 34 | Clo, TT, Mel, OKT3 | MMF | — | MMF | — |
| 6 | 0.4 | Tay-Sachs | Haplo | +/+ | 5 | Bu, Cy, TT, OKT3 | MMF | — | — | — |
| 7 | 59 | AML | Haplo | +/+ | 80 | Flu, Mel, TT, OKT3 | MMF | Gut III | MMF | — |
| 8 | 13 | RMS | Haplo | +/+ | 60 | Flu, Cy Treo | CSA, MTX | — | CSA | — |
| 9 | 6 | ALL | Haplo | +/+ | 18 | Clo, TT, Mel, OKT3 | MMF | Skin I, gut II, BOOP | MMF, Etanercept | Gut I |
| 10 | 52 | AML | Haplo | +/+ | 65 | Flu, TT, TLI, OKT3 | — | — | — | — |
| 11 | 20 | ALL | Third-party MMUD after cord blood SCT | −/+ | 52 | Flu, Cy, OKT3 | CSA, MMF | Skin II | — | — |
| 12 | 37 | MDS | MUD | +/+ | 63 | Bu, Cy, Alemtuzumab | CSA, MMF | Skin I-II (suspected) | CSA | — |
| 13 | 48 | ALL | MMUD | +/+ | 62 | TBI, Cy, ATG | CSA, MTX | — | CSA, Prednisolone | — |
| 14 | 7 | JMML | Haplo | +/+ | 17 | Bu, Cy, Mel, OKT3 | MMF | — | — | — |
| 15 | 42 | AML | MRD | +/+ | 55 | Flu, Bu, ATG | CSA | Skin II | — | — |
| 16 | 7 | ALL | Haplo | +/+ | 18 | Flu, TT, Mel, OKT3 | CSA, MMF | Skin II and gut III | Tacrolimus, MMF | Skin I |
| 17 | 46 | AML | Third-party MMUD after cord blood SCT | −/+ | 84 | Flu, Cy | CSA; MMF | Gut I-II | MMF | Gut I |
| 18 | 26 | AML | Haplo | +/+ | Flu, TT, Mel, OKT3 | — | — | — | — |
IgG indicates immunoglobulin G; GVHD, graft-versus-host disease; AML, acute myelocytic leukemia; Flu, fludarabin; TT, thiotepa; Mel, melphalan; CSA, cyclosporine A; MMF, mycophenolate mofetil; MUD, matched unrelated donor; Treo, treosulfan; ATG, antithymocyte globulin; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; Clo, clofarabin; Bu, busulfan; Cy, cyclophosphamide; RMS, rhabdomyosarcoma; MTX, methotrexate; BOOP, bronchiolitis obliterans-organizing pneumonia; TLI, total lymphoid irradiation; MMUD, mismatched unrelated donor; MDS, myelodysplastic syndrome; TBI, total body irradiation; JMML, juvenile myelomonocytic leukemia; and MRD, matched related donor.
Mean age, 25 ± 19 years.
†Mean body weight, 47 ± 24 kg.